Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp for MRD+ AML Prior to AlloHCT
NCT05720988Phase 1Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of tagraxofusp in acute myeloid leukemia (AML) (2 cohorts), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Dose-limiting toxicity up to 42 days. Planned start Aug 2024; status: withdrawn.
02
Drugs
tagraxofusp
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05720988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720988.